Advertisement

Headache Classifications and Medically Resistant Headaches

  • Alexander FeoktistovEmail author
Chapter

Abstract

This chapter reviews the history of migraine headaches and development of the first headache classification. The most current international classification of headache disorders is reviewed with the main focus being around those headache types that frequently represent therapeutic challenges. Key symptoms that may guide the practitioner in the diagnostic process of these headache conditions are discussed with special attention devoted to the medically resistant headaches. This chapter will discuss diagnostic challenges and commonly suggested diagnostic criteria that should be helpful in deciding when it should be appropriate to refer patient to a headache specialist and when to apply an interventional treatment strategy.

Keywords

Cluster Headache Chronic Migraine Migraine Headache Headache Disorder Medication Overuse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Clifford FR. The history of migraine from Mesopotamian to Medieval times. Cephalalgia. 1995;15 Suppl 15:1–3.Google Scholar
  2. 2.
    Adams F. The extant works of Aretaeus, the Cappadocian. London: New Sydenham Society; 1856.Google Scholar
  3. 3.
    Critchley M. Migraine: from Cappadocia to queen square. In: Smith R, editor. Background to migraine. London: Heinemann; 1967. p. 16–21.Google Scholar
  4. 4.
    Kuehn CG. Claudii Galeni opera omnia, vol. 12. Leipzig: Officina Car. Cnoblochii; 1826.Google Scholar
  5. 5.
    Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia. 2004;24 Supp 1:9–160.Google Scholar
  6. 6.
    Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia. 2008;28(8):877–86.PubMedCrossRefGoogle Scholar
  7. 7.
    Schulman EA, Lake 3rd AE, Goadsby PJ, Peterlin B, Siegel S, Markley HG, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008;48(6):778–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Schulman EA, Brahin EJ. Refractory headache: historical perspective, need, and purposes for an operational definition. Headache. 2008;48(6):770–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Silberstein S, Dodick D, Pearlman S. Defining the pharmacological intractable headache for clinical trials and clinical practice. Headache. 2010;50:1499–506.PubMedCrossRefGoogle Scholar
  10. 10.
    Kruit MC, Launer LJ, Overbosch J, van Buchem MA, Ferrari MD. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia. 2009;29(3):351–9.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience. 2001;106(4):793–800.PubMedCrossRefGoogle Scholar
  12. 12.
    Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G. Hypothalamic activation in spontaneous migraine attacks. Headache. 2007;47(10):1418–26.PubMedGoogle Scholar
  13. 13.
    Matharu MS, Bartsch T, Ward N, Frackowiak RS, Weiner R, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain. 2004;127(Pt 1):220–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache. 1987;27(8):416–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang W, Schoenen J. Interictal potentiation of passive “oddball” auditory event-related potentials in migraine. Cephalalgia. 1998;18(5):261–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87(3):543–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005;366:371–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Tournier-Lasserve E. Hemiplegic migraine, episodic ataxia type 2, and the others. Neurology. 1999;53:3–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Feoktistov A, Filatova E, Vein A. Abuse headache. Zh Nevrol Psikhiatr Im S S Korsakova. 1999;12:58–61.Google Scholar
  20. 20.
    Warner J. Frequent migraine and migraine status without tension-type headaches: an unusual presentation of rebound headaches. Cephalalgia. 2003;23(4):309–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26(6):742–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Feoktistov A. Clinico-psychophysiological peculiarities of the patients with abuse headache. Monograph (dissertation for Ph.D. degree), Ministry of Public Health of Russian Federation, Moscow Medical Academy, Moscow; 2001. p. 1–168.Google Scholar
  24. 24.
    Feoktistov A, Filatova E, Vein A. Psychophysiological characteristic of groups of patients with analgesic rebound headache. Zh Nevrol Psikhiatr Im S S Korsakova. 2002;10:13–7.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Clinical ResearchDiamond Headache ClinicGlenviewUSA

Personalised recommendations